Subsequent Events	9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events The Company has completed an evaluation of all subsequent events after the unaudited condensed consolidated balance sheet date of September 30, 2023 through the date these condensed consolidated financial statements were issued to ensure that these condensed consolidated financial statements include appropriate disclosure of events both recognized in the condensed consolidated financial statements as of September 30, 2023, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. The Company had no non-recognizable subsequent events. In October 2023, the Company provided a 90-day notice to terminate the Aurigene license agreement effective in January 2024. In October 2023, the Company filed a prospectus supplement with the SEC, which covered the offering, issuance and sale by the Company of up to an aggregate of $59.7 million of the Company’s common stock from time to time in at-the-market offerings pursuant to an Open Market Sale Agreement between the Company and Jefferies LLC, as sales agent. As of the issuance date of these condensed consolidated financial statements, no additional shares of common stock had been sold in ATM offerings since September 30, 2023. In October 2023, the Company dosed the first patient in the Phase 1 clinical trial of polycythemia vera (“PV”) for DISC-3405. Per the license agreement, upon achievement of initiation of a Phase 1 clinical trial, a milestone payment of $5.0 million is due to Mabwell.

Subsequent Events

9 Months Ended

Sep. 30, 2023

17. Subsequent Events

The Company has completed an evaluation of all subsequent events after the unaudited condensed consolidated balance sheet date of September 30, 2023 through the date these condensed consolidated financial statements were issued to ensure that these condensed consolidated financial statements include appropriate disclosure of events both recognized in the condensed consolidated financial statements as of September 30, 2023, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. The Company had no non-recognizable subsequent events.

In October 2023, the Company provided a 90-day notice to terminate the Aurigene license agreement effective in January 2024.

In October 2023, the Company filed a prospectus supplement with the SEC, which covered the offering, issuance and sale by the Company of up to an aggregate of $59.7 million of the Company’s common stock from time to time in at-the-market offerings pursuant to an Open Market Sale Agreement between the Company and Jefferies LLC, as sales agent. As of the issuance date of these condensed consolidated financial statements, no additional shares of common stock had been sold in ATM offerings since September 30, 2023.

In October 2023, the Company dosed the first patient in the Phase 1 clinical trial of polycythemia vera (“PV”) for DISC-3405. Per the license agreement, upon achievement of initiation of a Phase 1 clinical trial, a milestone payment of $5.0 million is due to Mabwell.